UK Startup Tozaro Raises $7.4M to Slash Gene Therapy Costs

Jan de Vries · 2026-02-16

Let's talk about something that's both incredibly exciting and frustratingly expensive: cell and gene therapies. They're medical miracles, but their price tags are out of this world. That's why the news out of Bedford, UK, is so significant. Tozaro, a biotech company, just secured $7.4 million in fresh funding. Their mission? To use a clever 'Smart Polymer' platform to dramatically cut the production costs of these life-saving treatments. This round was led by Mercia Ventures and pushes their total funding to over $29 million. ### Why This Funding Matters Think of it this way. The science is there, but the cost to make these therapies is holding everything back. It's like having a blueprint for a revolutionary car but the factory to build it costs a billion dollars. Tozaro is working on making that factory affordable. CEO Jason Slingsby put it perfectly: "By improving manufacturing yields and quality while reducing costs, we can remove the barriers and enable more patients to access these life-changing cell therapies." That's the heart of it. It's not just about the tech; it's about getting treatments to people who desperately need them. ### A Wave of European Biotech Investment Tozaro isn't alone in this push. 2025 has seen serious money flowing into similar tech across Europe: - EpilepsyGTx in Cambridge, UK, raised $30 million for a gene therapy for severe epilepsy. - Denmark's Fuse Vectors got $5.3 million to work on a cell-free viral vector platform. - Sweden's BOOST Pharma secured $3.3 million for a stem cell therapy candidate. Together, that's about $38.5 million invested in making these advanced therapies more viable. It shows a clear trend: investors are betting big on solving the manufacturing bottleneck. ### How Tozaro's Smart Polymers Work Founded in 2015, Tozaro uses molecular modeling and machine learning to design special polymers. Here's the simple breakdown: - **Traditional methods** use proteins and peptides, which have about 20 building blocks (amino acids). - **Tozaro's platform** uses over 500 chemical groups to create its binding compounds. That's a much bigger playground for discovery. They can explore a vast new chemical space to find cheaper, more stable, and more effective solutions. They're currently developing their tech for use in making the viral vectors needed for CAR-T cancer therapies and other gene treatments. ### The Staggering Cost Problem Let's get real about the numbers, because they're shocking. We're talking about treatments that cost hundreds of thousands, even millions, per patient. - **CAR-T therapies** for cancers like leukemia can cost over $455,000 per patient. - **Gene therapies** for rare genetic diseases, like some forms of childhood blindness, can exceed $1.2 million per patient. That's simply not sustainable for healthcare systems or for patients. Mark Payton, CEO of Mercia Asset Management, highlighted the core issue: "The growth of this exciting new generation of biological therapeutics is being held back by the extreme cost of production." Tozaro's approach is smart because it focuses on the manufacturing process itself. They're not developing a new drug and facing those massive clinical trial risks. Instead, they're building a better, cheaper tool that every drug maker could potentially use. It's a classic case of working smarter, not just harder. The company is already testing its technology with manufacturing partners. The goal is clear: turn these groundbreaking medical discoveries from luxury items into accessible treatments. For anyone watching the biotech space, Tozaro's progress is a story worth following.